The American Heart Association and Heart Failure Society released a joint scientific statement summarizing the effects of type 2 diabetes management on heart failure outcomes.
Cancer death rates declined for adults aged 45 to 64 years from 1999 to 2017, while heart disease death rates decreased to 2011 and then increased.
The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to PB2452 (PhaseBio), an investigational reversal agent for ticagrelor.
When politicians attempt to make changes to health policy based on sentiments rather than on evidence-based conclusions, physicians often find themselves trying to meet unrealistic expectations.
Wearable devices can be used to diagnose cardiac rhythm abnormalities, but further investigation is necessary to optimize and integrate such technology into health care.
Researchers evaluated the national burden of financial hardship from medical bills among persons with atherosclerotic cardiovascular disease, as well as the fallout from such a problem, including financial distress, food insecurity, and cost-related medication nonadherence.
The Food and Drug Administration (FDA) has approved a new generic version of Diovan (Novartis) that does not contain N-nitrosodimethylamine (NDMA) or N-nitrosodiethylamine (NDEA), 2 potentially carcinogenic impurities identified in several recalled valsartan products.
Researchers found that patients with coronary artery disease enrolled in Medicare Advantage had a slightly higher comorbidity burden and received higher quality care than their traditional fee-for-service Medicare counterparts.
As the link between diabetes and PAD becomes more evident, clinicians can best serve patients with these comorbidities by working collaboratively to prevent serious complications.
African Americans have a higher burden of sudden cardiac death than whites, especially among women.
